Name | Number of supported studies | Average coverage | |
---|---|---|---|
cardiac muscle cell | 5 studies | 31% ± 9% |
Insufficient scRNA-seq data for expression of NMRK2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
heart | 100% | 39847.89 | 860 / 861 | 0% | 0 | 0 / 0 |
muscle | 100% | 11173.09 | 800 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 99% | 40.76 | 79 / 80 |
adrenal gland | 16% | 44.53 | 40 / 258 | 31% | 6.19 | 72 / 230 |
prostate | 20% | 103.36 | 48 / 245 | 22% | 0.93 | 111 / 502 |
skin | 1% | 9.70 | 11 / 1809 | 40% | 15.71 | 188 / 472 |
kidney | 18% | 45.25 | 16 / 89 | 21% | 95.38 | 190 / 901 |
esophagus | 33% | 141.67 | 482 / 1445 | 1% | 0.03 | 2 / 183 |
blood vessel | 27% | 116.35 | 364 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 18% | 2.53 | 8 / 45 |
lymph node | 0% | 0 | 0 / 0 | 17% | 0.61 | 5 / 29 |
uterus | 3% | 5.90 | 5 / 170 | 7% | 2.72 | 32 / 459 |
ovary | 4% | 7.04 | 7 / 180 | 4% | 0.20 | 19 / 430 |
stomach | 3% | 9.20 | 11 / 359 | 5% | 0.41 | 13 / 286 |
lung | 3% | 77.57 | 15 / 578 | 3% | 0.14 | 39 / 1155 |
bladder | 5% | 5.57 | 1 / 21 | 1% | 0.22 | 6 / 504 |
brain | 1% | 2.81 | 25 / 2642 | 4% | 0.10 | 27 / 705 |
thymus | 2% | 15.72 | 12 / 653 | 3% | 0.08 | 17 / 605 |
intestine | 2% | 3.45 | 18 / 966 | 2% | 0.11 | 12 / 527 |
breast | 2% | 28.78 | 11 / 459 | 1% | 0.13 | 16 / 1118 |
adipose | 4% | 21.07 | 44 / 1204 | 0% | 0 | 0 / 0 |
liver | 0% | 0 | 0 / 226 | 3% | 0.51 | 11 / 406 |
pancreas | 1% | 0.75 | 2 / 328 | 2% | 0.06 | 3 / 178 |
peripheral blood | 2% | 5.39 | 20 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0009435 | Biological process | NAD biosynthetic process |
GO_0019674 | Biological process | NAD metabolic process |
GO_0045662 | Biological process | negative regulation of myoblast differentiation |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0050262 | Molecular function | ribosylnicotinamide kinase activity |
GO_0061769 | Molecular function | ribosylnicotinate kinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
Gene name | NMRK2 |
Protein name | Nicotinamide riboside kinase 2 Nicotinamide riboside kinase 2 (NRK 2) (NmR-K 2) (EC 2.7.1.22) (Integrin beta-1-binding protein 3) (Muscle integrin-binding protein) (MIBP) (Nicotinic acid riboside kinase 2) (EC 2.7.1.173) (Ribosylnicotinamide kinase 2) (RNK 2) (Ribosylnicotinic acid kinase 2) |
Synonyms | ITGB1BP3 NRK2 |
Description | FUNCTION: Catalyzes the phosphorylation of nicotinamide riboside (NR) and nicotinic acid riboside (NaR) to form nicotinamide mononucleotide (NMN) and nicotinic acid mononucleotide (NaMN). Reduces laminin matrix deposition and cell adhesion to laminin, but not to fibronectin. Involved in the regulation of PXN at the protein level and of PXN tyrosine phosphorylation. May play a role in the regulation of terminal myogenesis. . |
Accessions | M0QX67 ENST00000597889.1 M0R0T8 ENST00000616156.4 [Q9NPI5-3] ENST00000168977.7 [Q9NPI5-1] ENST00000593949.1 [Q9NPI5-3] Q9NPI5 ENST00000599576.5 |